

Elevated plasma tissue factor levels in neonates with umbilical arterial catheter-associated thrombosis

SP TAY, *B.Biomed.Sc., M.Med.Sc.*, SK CHEONG, *FRCP, FRCPA* and *NY BOO, *FRCP, FAMM*.

*Departments of Pathology and *Paediatrics, Faculty of Medicine, Universiti Kebangsaan Malaysia, 56000 Kuala Lumpur, Malaysia.*

Abstract

Catheterization of the umbilical artery has been a useful aid in the management of sick neonates for the past few decades. However, it is associated with various complications. Reported studies strongly suggest a significant role of intravascular catheterization in the development of aortic thrombi. Increase in thrombosis of large vessels is believed to be related to mechanical injury in the catheterized vessels, which provide direct exposure of blood to tissue factor (TF), the primary cellular initiator of the extrinsic coagulation pathway. This study was conducted to determine the levels of plasma TF, tissue factor pathway inhibitor (TFPI) and D-dimer (DD) in infants with umbilical arterial catheter (UAC)-associated thrombosis. Quantification of TF was carried out using an in-house sandwich ELISA, whereas TFPI and DD levels were measured with commercial immunoassay kits. Infants with UAC inserted were found to have significantly higher levels of plasma TF ($p < 0.001$) than baseline levels. However, there were no significantly elevated levels of TFPI or DD. Infants with UAC-associated thrombosis demonstrated a greater increase of TF level (median: 414.5 pg/mL; range: -76.0, 6667.0) than infants without UAC-associated thrombosis (105.0 pg/mL; -976.0, 9480.0; $p = 0.009$) following UAC insertion. Our findings indicate that quantification and monitoring of TF levels could predict thrombus formation in infants with indwelling UAC. Following umbilical arterial catheterisation, infants with an approximately 3-fold rise in plasma TF levels were most at risk of developing abdominal aorta thrombosis as confirmed by real-time abdominal ultrasonography.

Key words: tissue factor, tissue factor pathway inhibitor, D-dimer, umbilical arterial catheterisation, thrombosis and neonates.

INTRODUCTION

Catheterization of umbilical vessels to facilitate management of the sick or critically ill newborn infants has been a routine practice in most neonatal intensive care units (NICU). The use of an indwelling catheter in an umbilical vessel can lead to improved care of sick infants; however, this useful diagnostic and therapeutic tool may also cause serious complications. The potential complications include thrombosis; embolism; vasospasm; vascular perforation; infection; haemorrhage; gastrointestinal, renal, and limb tissue damage; hepatic necrosis; hydrothorax; cardiac arrhythmias; pericardial effusion and tamponade; and erosion of the atrium and ventricle.¹ In addition, the incidence of neonatal hypertension is significantly higher in infants inserted with umbilical arterial catheter (UAC).²⁻⁴

Thrombosis has been reported to be the most common complication, with an incidence ranging from as low as 4.7% to as high as 95%.^{3,5-16} Since catheterization is undoubtedly of great usefulness, an understanding of the mechanisms and risk factors contributing to the development of thrombosis and infarction may help to reduce the incidence of such complications.

Tissue factor (CD142; tissue thromboplastin; coagulation factor III, TF), a ubiquitous membrane-anchored low molecular weight (45-47 kD) glycoprotein, is a high-affinity cellular receptor and cofactor for factor VII/VIIa.¹⁷⁻²⁰ This single chain glycoprotein is the primary cellular initiator of the coagulation protease cascade. Under normal circumstances, TF is present at sites anatomically separated from flowing blood.²¹ It is constitutively expressed in a cell-specific manner

Address for correspondence and reprint requests: Professor Cheong Soon Keng, Department of Medicine, Clinical School, International Medical University, Jalan Rasah, 70300 Seremban, Negeri Sembilan, Malaysia. Tel: (+606) 7677798 Ext.166; Fax: (+603) 7677709; E-mail: soonkeng_cheong@imu.edu.my

in tissues surrounding vascular structures, and in cells delimiting organ boundaries. The physiological cellular distribution of TF appears to form a 'haemostatic envelope', ensuring prompt initiation of coagulation in the event of vascular rupture.^{21,22} As a potent procoagulant, TF is believed to have a critical pathophysiological role in thromboembolic disorders and the lethal coagulopathy of septicemia in pathological conditions. Indeed, recent studies have suggested that TF also plays non-haemostatic roles in embryonic vascular development,²³ intracellular signaling,²⁴⁻²⁶ neovascularization and tumour metastasis.²⁶⁻²⁸

The TF-VIIa complex initiates a cascade of proteolytic reactions resulting in thrombin production – the penultimate step in haemostasis.²⁹ TF function is regulated by feedback inhibition involving a Kunitz-type inhibitor, TF pathway inhibitor (TFPI).³⁰ Intricately interwoven with the clotting mechanism is the process of fibrinolysis, which is achieved by a potent plasma proteolytic enzyme, plasmin. The digestion of fibrin by plasmin produces fibrin degradation products, and one of them is fibrin D-dimer (DD), a cross-linked fragment that is not produced by the digestion of fibrinogen.³¹ The fibrinolytic system is essential for removing fibrin deposits as part of vessel healing to reestablish blood flow and preserve vascular patency.

Considering mechanical factors, there are reports concerning the ability of catheters to produce considerable trauma.^{5,6} Additionally, increase in thrombosis of large vessels is believed to be related to direct mechanical injury and alteration of flow in catheterized vessels.⁸ The traumatized vessels provide direct exposure of blood to collagen and TF, which will subsequently initiate the coagulation system. TF antigen in plasma may reflect endothelial injury and cell destruction in TF-containing tissues, and as yet there is no report demonstrating the correlation of TF, TFPI and DD levels with the occurrence of UAC-associated thrombosis. We therefore conduct this study to evaluate the clinical significance of TF, TFPI and DD levels, in newborn infants with UAC-associated thrombosis.

MATERIALS AND METHODS

Study subjects

A total of 94 consecutive newborn infants admitted to the NICU of Hospital Universiti Kebangsaan Malaysia from August 1998 to August 2000 with UAC inserted were eligible for the study. Infants who died before the removal of UAC, and who developed complication of septicemia were excluded from the study. Characteristics of the infants were summarised in Table 1.

TABLE 1. Characteristics of the infants with umbilical arterial catheter (UAC) inserted.

Characteristics	Infants with UAC (n = 94)
Gender	
Male (%)	60.6
Female (%)	39.4
Race	
Malay (%)	61.7
Chinese (%)	33.0
Indian and others (%)	5.3
Mode of Delivery	
SVD (%)	52.1
ID (%)	47.9
Birthweight (g)†	1973.5 ± 1019.7
Gestation (wk)†	33.2 ± 5.5
Apgar Score (1 min)†	5.2 ± 3.0
Apgar Score (5 min)†	6.7 ± 3.2

SVD, spontaneous vertex delivery; ID, instrumental delivery (lower segment caesarean section, breech, vacuum, forceps).

† Values are mean ± SD.

Blood collection and plasma preparation

Syringe technique was applied to draw 0.5-1 mL of blood from the UAC after obtaining consent from the infant's parents under study. Paired blood samples from the infants were taken at the time of insertion of UAC (initial-UAC), and just before the removal of UAC (end-UAC). Initial-UAC sample was taken before commencement of infusion of heparinised saline. For end-UAC sample, 1 mL of blood was withdrawn into a syringe before a sample of 0.5-1 mL of blood was collected into another sterile unused syringe for analysis. This is to prevent contamination of the specimen by the infusion fluid. Platelet-poor-plasma was subsequently obtained by drawing 9 vol of the blood into 1 vol of 3.8% (129 mM) trisodium citrate, and by centrifugation at 3000 rpm for 30 min at 4°C. The plasma was then aliquoted, snap-frozen and stored at -80°C for further testing. Blood separation was performed within 2 h of collection to minimize any effects of storage. Clotted and grossly haemolyzed samples were excluded from the study.

Umbilical arterial catheterization

The position of the tip of the UAC was confirmed by radiography. The UAC was inserted until its tip was located in the infant's aorta at a level between the sixth and ninth thoracic vertebrae. Whenever radiography showed that the tip of any UAC was at a level below the ninth thoracic vertebra, the UAC was withdrawn partially until its tip was at a level between the second and fourth lumbar vertebrae below the level of the infant's renal vessels. The tip of the UAC was positioned such to minimize the risk of causing thrombosis or arterial spasm to the origin of the renal arteries. Only polyvinyl Argyle catheters with end holes were used during the study period. All catheters were infused with heparinised intravenous fluid at a concentration of 1.0 U of heparin/mL. No infant received infusion of calcium solution via UAC.

Detection of thrombus formation

The first abdominal ultrasonography was performed shortly before or after the insertion of UAC. Within 24-48 h after removal of UAC, ultrasound scanning was repeated. This is the standard clinical pathway to monitor UAC-associated thrombosis in our NICU, based on the findings of our previous study.³ Real-time ultrasound examination was performed in the NICU at the crib side by the attending neonatologists, using a 7.5 MHz linear probe

(sometimes a 7.5 MHz sector probe was used for tiny infants) on an ultrasound machine (Apogee 800 Model, Advance Technology Laboratory, Bothell, Washington, USA). The abdominal vascular system was systematically examined utilising both 2-D and colour Doppler modes via the coronal views and transverse views from both flanks of the infant's abdomen, and by the transverse and longitudinal views at the infant's epigastric region. The following structures of each infant were scanned: abdominal aorta, origins of coeliac artery and superior mesenteric artery, proximal common iliac arteries, renal arteries, inferior vena cava, hepatic veins, portal vein, renal veins, the liver, adrenal glands, and kidneys. A thrombus was diagnosed ultrasonographically when a persistent intravascular echo was observed in two planes, attached either to the vessel wall or to the catheter.³² Colour Doppler was used to confirm the presence of a mass effect of abnormal echoes at these sites.

In-house TF ELISA

TF antigen was measured by a previously published in-house direct sandwich ELISA,³³ which employed two antibodies against human TF. Briefly, the microtiter plate (Immulon® 2HB Removawell®, Dynex Technologies, USA) was coated at 4°C overnight with 1250 ng/mL mouse anti-human TF MAb (Enzyme Research Laboratories Inc., Indiana, USA). After blocking with buffer containing 5% (wt/vol) skimmed milk and 0.5% (vol/vol) Tween 20, samples diluted with PBS containing 1.5% skimmed milk and 0.5% Tween 20 were incubated for 1 h at 27°C. After five washing steps, 2 µg/mL of horseradish peroxidase-labelled sheep IgG anti-human TF (Affinity Biologicals Inc., Ontario, Canada) was added and incubated for 1 h at 27°C. TMB (3,3',5,5'-tetramethylbenzidine; Sigma Co., USA) was utilized as substrate. Absorbance was measured spectrophotometrically in Multiskan MS microplate reader (Labsystem, Finland). Samples were assayed in triplicate and the respective TF levels were interpolated from the linear portion (10-4000 pg/mL) of the standard curve constructed from recombinant TF (American Diagnostica Inc., Greenwich, CT, USA). The assay demonstrated low intra- (3-9 CV%; coefficient of variation) and inter-assays (6-14 CV%) variability, as well as satisfactory analytical recovery (92-104 %).

TFPI and DD

Total TFPI and DD were measured with Asserachrom® Total TFPI (Diagnostica Stago, Asnières-Sur-Seine, France) and TintElize® D-dimer (Biopool® International, CA, USA) commercial ELISA kits respectively.

Statistical analysis

Statistical analysis was carried out using SPSS Version 9.0. Tests of normality were performed to verify the distribution of continuous variables. Paired Student's *t*-test (or Wilcoxon signed-rank test for not-normally distributed variables) was applied to assess the differences between initial-UAC and end-UAC samples. Unpaired Student's *t*-test (or Mann-Whitney U test for not-normally distributed variables) was used to compare variables between two groups (with thrombus vs. without thrombus; alive vs. dead). All statistical tests were two-tailed, and *p* value < 0.05 was considered to be statistically significant.

RESULTS*Initial-UAC vs. end-UAC samples*

Table 2 compares the levels of plasma TF, TFPI and DD in initial-UAC and end-UAC samples. The levels of TF were significantly increased after UAC insertion (*p* < 0.001). However, TFPI and DD levels showed no significant increase.

Development of UAC-associated aortic thrombus

No thrombus was detected by ultrasonography in any infant at the time of insertion of UAC. Abdominal aortic thrombi were detected in 22 infants upon removal of UAC. The duration of UAC *in-situ* was longer in infants who developed

thrombi (median: 5.5 days, range: 1, 24) than those without thrombi (median: 4 days, range: 1, 25), although the difference was not statistically significant (*p* = 0.137).

Infants with UAC-associated thrombus vs. infants without UAC-associated thrombus

Infants who developed UAC-associated thrombosis demonstrated greater increase in TF levels after catheterization (median: 414.5 pg/mL; range: -76.0, 6667.0) than infants without UAC-associated thrombosis (median: 105.0 pg/mL; range: -976.0, 9480.0; *p* = 0.009) (Table 3). TF levels in the initial-UAC samples were not significantly different between infants who developed thrombus (median: 232.0 pg/mL; range: 66.0, 1579.0), and those without thrombus (median: 253.0 pg/mL; range: 36.0, 2125.0; *p* = 0.9). Meanwhile, there were no significant differences in the increase of TFPI and DD levels after catheterization, between these two groups of infants.

Alive vs. dead infants

During the study, 89 infants receiving UAC insertion survived until discharge while 5 died subsequently after the removal of UAC. Infants who survived showed non-significant difference of initial-UAC TF levels (median: 251.0 pg/mL; range: 36.0, 2125.0) when compared with those who died (median: 589.0 pg/mL; range: 153.0, 1442.0; *p* = 0.2). There were no significant differences in the increase in levels of TF, TFPI and DD levels after catheterization, between infants who survived and those who died (Table 4).

TABLE 2. Comparison of tissue factor (TF), tissue factor pathway inhibitor (TFPI) and D-dimer (DD) levels in initial-umbilical arterial catheterization (UAC) and end-UAC samples.

	Initial-UAC (<i>n</i> = 94)	End-UAC (<i>n</i> = 94)	<i>p</i> values
TF (pg/mL)†	253.0 (36.0, 2125.0)	441.5 (39.0, 9645.0)	<i>p</i> < 0.001*
TFPI (ng/mL)‡	55.9 ± 31.0	59.0 ± 32.6	0.4
DD (ng/mL)†	406.8 (47.1, 3815.4)	432.4 (61.0, 3507.7)	0.8

Data are expressed as † median (range) or ‡ mean ± SD.

* Denotes statistical significance.

TABLE 3. Comparison of the increase of plasma tissue factor (TF), tissue factor pathway inhibitor (TFPI) and D-dimer (DD) levels between infants with and without umbilical arterial catheter (UAC)-associated thrombosis.

Difference between end-UAC and initial-UAC samples	Infants with UAC-associated thrombus (n = 22)	Infants without UAC-associated thrombus (n = 72)	p values
TF (pg/mL)†	414.5 (-76.0, 6667.0)	105.0 (-976.0, 9480.0)	0.009*
TFPI (ng/mL)‡	4.1 ± 47.7	2.7 ± 34.2	0.9
DD (ng/mL)†	23.9 (-3117.2, 1714.4)	32.5 (-3065.0, 3168.3)	0.9

Data are expressed as † median (range) or ‡ mean ± SD.

* Denotes statistical significance.

TF/TFPI ratio

Infants with UAC-associated thrombosis showed greater increase of TF/TFPI ratio than infants without UAC-associated thrombosis; however, this difference did not reach the statistical significant level ($p = 0.06$; Table 5). This ratio was also not statistically different between infants who were alive and those who died.

DISCUSSION

To our knowledge this is the first study to demonstrate a significant association between umbilical arterial catheterisation and an increase in plasma TF levels ($p < 0.001$) in newborn infants. In an experimental study reported by Chidi *et al.*,³⁴ catheterization of the abdominal aorta with small umbilical artery catheters consistently produced significant intimal injury and endothelium disruption. The increased end-UAC TF levels in the present study suggested that direct mechanical injury of vascular

endothelium, which was the extravascular TF reservoir, eliciting acute response to vascular injury. The finding was unlikely due to the heterogeneous study population (Table 1). There was no significant correlation noticed between the TF levels and birthweight or TF levels and gestational week, although the infant's birthweight and gestational week ranged widely from 265-4890 g (birthweight ≥ 2500 g: $n = 31$; birthweight < 2500 g: $n = 63$) and 24-43 wk (term gestation: $n = 35$; preterm gestation: $n = 59$) respectively. Similarly, no significant correlation was observed between the TF levels and Apgar scores despite of the wide ranges of Apgar scores at 1 min (0-9) and 5 min (0-10).

It is interesting to note that there were no significant differences between the end-UAC TFPI and DD levels and those in the initial-UAC samples. We speculated that the measured TFPI concentration was the total TFPI presented in plasma, which comprised the TF-FVIIa

TABLE 4. Comparison of the increase of plasma tissue factor (TF), tissue factor pathway inhibitor (TFPI) and D-dimer (DD) levels between umbilical arterial catheterized-infants who survived and those who died.

Difference between end-UAC and initial-UAC samples	Alive (n = 89)	Dead (n = 5)	p values
TF (pg/mL)†	133.0 (-976.0, 9480.0)	10.0 (-114.0, 5553.0)	0.3
TFPI (ng/mL)‡	3.1 ± 37.0	1.6 ± 51.1	0.9
DD (ng/mL)†	37.2 (-3117.2, 3168.3)	-51.2 (-2957.2, 540.0)	0.4

Data are expressed as † median (range) or ‡ mean ± SD.

complexes, bound and free forms of TFPI. The active form of TFPI could not be determined in the present study. Meanwhile, the DD had most probably reached its maximum levels where the production of this marker had achieved the saturation state, as its levels measured in the neonates in the present study, whether in initial or end-samples were very high when compared with levels in normal adults [mean 40 ng/mL³⁵].

In a previous study, Boo *et al.*³ reported that, after controlling for various potential confounders, the only significant risk factor associated with the development of abdominal aortic thrombosis following insertion of UAC was the duration of UAC *in situ*. They found that for every additional day of UAC remaining *in situ*, the adjusted odds ratio of developing aortic thrombosis was 1.2 (95% C.I.: 1.1, 1.3; $p = 0.002$). In the present study, infants who developed aortic thrombi demonstrated greater increase of TF levels than those who did not develop such thrombus ($p = 0.009$), after umbilical arterial catheterization (Table 3). Although not statistically significant, infants with UAC-associated thrombosis in the present study also had their UAC left *in-situ* for longer duration than those without thrombosis. The most likely explanation for this lack of statistical significance was the much smaller sample size of infants with thrombosis in the present study than our previous one.

The findings of the present study suggest that serial measurement of TF may help to identify infants at risk of developing aortic thrombosis when there is a need of a UAC to remain *in situ* for longer period of time. An approximately 3-fold increase of TF levels demonstrated moderate diagnostic indices of thrombus formation

(sensitivity = 55%, specificity = 83%, positive predictive value = 50%, negative predictive value = 86%). These infants therefore may need to be monitored more closely by abdominal ultrasonography as well. The finding of this study was in agreement with the accumulating evidence that increased TF production could be an important causative factor of thromboembolic state in pathological conditions.^{20,36,37} Conversely, neither the increase in TFPI nor DD levels was significantly different between infants with or without thrombosis (Table 3).

On the other hand, no significant differences were shown in the increase of these three haemostatic markers between infants who survived and those who died (Table 4). In a study on patients with disseminated intravascular coagulation (DIC), there was no significant difference in plasma TF levels between the DIC patients with good outcome and those with poor outcome.³⁸ Thus, based on our data, we might surmise that these markers were not useful in predicting the survival of infants receiving UAC insertion. However, the number of infants who died in this study was too small ($n = 5$) to draw any definite conclusion.

The activity of TF is tightly regulated *in vivo* by TFPI, which inhibits the activity of TF-VIIa complex by forming a stable, inactive quaternary complex composing of TFPI, TF, Factor VIIa and Xa, thereby blocking the generation of thrombin.³⁰ Thus, the increase TF/TFPI ratio might contribute to a markedly hypercoagulable state that could progress to thrombus. In infants with UAC-associated thrombosis, the thrombotic tendency may be induced by uncontrolled elevation of TF levels that are not sufficiently balanced by TFPI. In

TABLE 5. Relationship between tissue factor (TF)/tissue factor pathway inhibitor (TFPI) ratio and outcome of infants receiving umbilical arterial catheter (UAC) insertion.

Outcome	TF/TFPI ratio†	<i>p</i> values
<i>UAC-associated thrombosis</i>		
Yes ($n = 22$)	8.9 (-4.5, 151.3)	0.06
No ($n = 72$)	1.6 (-40.1, 150.5)	
<i>Died</i>		
Yes ($n = 5$)	0.4 (-6.5, 150.5)	0.3
No ($n = 89$)	2.6 (-40.1, 151.3)	

Data are expressed as median (range).

† Difference between TF/TFPI (end-UAC) and TF/TFPI (initial-UAC) ratio

the present study, a greater increase of TF/TFPI ratio was noted in infants with UAC-associated thrombus than those without UAC-associated thrombus. The borderline lack of statistical significance ($p = 0.06$; Table 5) could be due to inadequate sample size.

In summary, infants inserted with UAC showed elevated levels of TF after catheterization. In particular, infants who developed aortic thrombus demonstrated a significantly greater increase in TF levels than infants who did not develop thrombus ($p = 0.009$). Our findings indicated that serial measurement of TF levels following insertion of UAC could predict possible impending thrombus formation, particularly when there is a 3-fold rise in TF levels. Based on this observation, the institution of prophylactic measures such as anti-TF or TFPI therapy, may help to deter the development of thrombus and minimize the morbidity of infants receiving UAC insertion. Although raised levels of plasma TF in infants with UAC-associated thrombosis may reflect the aetiopathogenesis of thrombosis, measurement of TF levels has moderate sensitivity to predict the development of thrombosis. The reason for this moderate sensitivity could be due to the fact that we are measuring the total amount of TF, but not the functional component of TF. In this regard, functional activity measurement of TF,^{39,40} may complement excellently to the immunochemical analysis of TF antigen levels, and thus will clarify some of the ambiguities that remain.

ACKNOWLEDGEMENTS

The authors are indebted to the neonatologists from Hospital Universiti Kebangsaan Malaysia for assisting in carrying out the abdominal ultrasonography. This study was fully funded by a research grant (IRPA no. 06-02-02-0067) from the Ministry of Science, Technology and Environment, Malaysia.

REFERENCES

- Green C, Yohannan MD. Umbilical arterial and venous catheters: placement, use, and complications. *Neonatal Netw* 1998; 17(6):23-8.
- Singh HP, Hurley RM, Myers TF. Neonatal hypertension. Incidence and risk factors. *Am J Hypertens* 1992; 5(2):51-5.
- Boo NY, Wong NC, Syed Zulkifli SZ, Lye MS. Risk factors associated with umbilical vascular catheter-associated thrombosis in newborn infants. *J Paediatr Child Health* 1999; 35(5):460-5.
- Flynn JT. Neonatal hypertension: diagnosis and management. *Pediatr Nephrol* 2000; 14(4):332-41.
- Cochran WD, Davis HT, Smith CA. Advantages and complications of umbilical artery catheterization in the newborn. *Pediatrics* 1968; 42(5):769-77.
- Gupta JM, Robertson NRC, Wigglesworth JS. Umbilical artery catheterization in the newborn. *Arch Dis Child* 1968; 43(229):382-7.
- Kitterman JA, Phibbs RH, Tooley WH. Catheterization of umbilical vessels in newborn infants. *Pediatr Clin North Am* 1970; 17(4):895-912.
- Wigger HJ, Bransilver BR, Blanc WA. Thromboses due to catheterization in infants and children. *J Pediatr* 1970; 76(1):1-11.
- Neal WA, Reynolds JW, Jarvis CW, Williams HJ. Umbilical artery catheterization: demonstration of arterial thrombosis by aortography. *Pediatrics* 1972; 50(1):6-13.
- Symansky MR, Fox HA. Umbilical vessel catheterization: indications, management, and evaluation of the technique. *J Pediatr* 1972; 80(5):820-6.
- Goetzman BW, Staldnik RC, Bogen HG, Blankenship WJ, Ikeda RM, Thayer J. Thrombotic complications of umbilical artery catheters: A clinical and radiographic study. *Pediatrics* 1975; 56(3):374-9.
- Olinsky A, Aitken FG, Isdale JM. Thrombus formation after umbilical arterial catheterisation. An angiographic study. *S Afr Med J* 1975; 49(36):1467-70.
- Mokrohisky ST, Levine RL, Blumhagen JD, Wesenberg RL, Simmons MA. Low positioning of umbilical-artery catheters increases associated complications in newborn infants. *N Engl J Med* 1978; 299(11):561-4.
- Wesstrom G, Finnstrom O, Stenport G. Umbilical artery catheterization in newborns. I. Thrombosis in relation to catheter type and position. *Acta Paediatr Scand* 1979; 68(4):575-81.
- Joseph R, Chong A, Teh M, Wee A, Tan KL. Thrombotic complications of umbilical arterial catheterization and its sequelae. *Ann Acad Med Singapore* 1985; 14(4):576-82.
- Berger C, Durand C, Francoise M, Gouyon JB. Ultrasonographic survey of the effect of umbilical arterial catheterization in newborn infants. *Arch Pediatr* 1994; 1(11):998-1003.
- Bach RR. Initiation of coagulation by tissue factor. *CRC Crit Rev Biochem* 1988; 23(4):339-68.
- Nemerson Y. Tissue factor and hemostasis. *Blood* 1988; 71(1):1-8.
- Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. *Thromb Haemost* 1991; 66(1):67-79.
- Ruf W, Edgington TS. Structural biology of tissue factor, the initiator of thrombogenesis in vivo. *FASEB J* 1994; 8(6):385-90.
- Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. *Am J Pathol* 1989; 134(5):1087-97.
- McVey JH. Tissue factor pathway. *Baillière's Clin Haematol* 1999; 12(3):361-72.

23. Carmeliet P, Mackman N, Moons L *et al.* Role of tissue factor in embryonic blood vessel development. *Nature* 1996; 383(6595):73-5.
24. Røttingen JA, Enden T, Camerer E, Iversen JG, Prydz H. Binding of human factor VIIa to tissue factor induces cytosolic Ca²⁺ signals in J82 cells, transfected COS-1 cells, Madin-Darby canine kidney cells and in human endothelial cells induced to synthesis tissue factor. *J Biol Chem* 1995; 270(9):4650-60.
25. Camerer E, Røttingen JA, Gjernes E *et al.* Coagulation factors VIIa and Xa induce cell signaling leading to up-regulation of the egr-1 gene. *J Biol Chem* 1999; 274(45):32225-33.
26. Konigsberg W, Kirchhofer D, Riederer MA, Nemerov Y. The TF:VIIa complex: clinical significance, structure-function relationships and its role in signaling and metastasis. *Thromb Haemost* 2001; 86(3):757-71.
27. Zhang Y, Deng Y, Luther T *et al.* Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. *J Clin Invest* 1994; 94(3):1320-7.
28. Ott I, Fischer EG, Miyagi Y, Mueller BM, Ruf W. A role of tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280. *J Cell Biol* 1998; 140(5):1241-53.
29. McVey JH. Tissue factor pathway. *Baillière's Clin Haematol* 1994; 7(3):469-84.
30. Rapaport SI. The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. *Thromb Haemost* 1991; 66(1):6-15.
31. Mosesson MW. Fibrin polymerization and its regulatory role in hemostasis. *J Lab Clin Med* 1990; 116(1):8-17.
32. Seibert JJ, Taylor BJ, Williamson SL, Szabo JS, Corbitt SL. Sonographic detection of neonatal umbilical artery thrombosis: clinical correlation. *Am J Roentgenol* 1987; 148(5):965-8.
33. Tay SP, Cheong SK, Boo NY. An in-house ELISA method for quantification of circulating tissue factor. *Malays J Pathol* 2002; 24(1):45-51.
34. Chidi CC, King DR, Boles ET Jr. An ultrastructural study of the intimal injury induced by an indwelling umbilical artery catheter. *J Pediatr Surg* 1983; 18(2):109-15.
35. van der Bom JG, Bots ML, Haverkate F *et al.* Activation products of the haemostatic system in coronary, cerebrovascular and peripheral arterial disease. *Thromb Haemost* 2001; 85(2):234-9.
36. Carson SD. Tissue factor-initiated blood coagulation. *Prog Clin Pathol* 1984; 9:1-14.
37. Semeraro N, Colucci M. Tissue factor in health and disease. *Thromb Haemost* 1997; 78(1):759-64.
38. Shimura M, Wada H, Wakita Y *et al.* Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. *Am J Hematol* 1997; 55(4):169-74.
39. Bach RR, Moldow CF. Mechanism of tissue factor activation on HL-60 cells. *Blood* 1997; 89(9):3270-6.
40. Schecter AD, Giesen PLA, Taby O *et al.* Tissue factor expression in human arterial smooth muscle cells. *J Clin Invest* 1997; 100(9):2276-85.